MedTrace Logo

Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients

NCT01812434 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-11-01

No results posted yet for this study

Summary

Hypothesis 1: Treatment of heart transplant recipients with sildenafil, a PDE-5 inhibitor, will improve small artery elasticity (SAE) when compared to placebo.

Hypothesis 2: PDE-5 inhibition will improve endothelial function, resulting in increased production of nitric oxide, reduced activation of circulating endothelial cells, and increased endothelial progenitor cells.

Conditions

  • Cardiac Allograft Vasculopathy

Interventions

DRUG

Sildenafil

20mg three time daily for 28 days

DRUG

Placebo

20 mg three times daily for 28 days

Sponsors & Collaborators

Principal Investigators

  • Monica M Colvin-Adams, MD.MS · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01812434 on ClinicalTrials.gov